Anavex Life Sciences Names Terrie Kellmeyer, Ph.D., as President and Chief Executive Officer and Member of the Board of Directors
Seasoned biopharmaceutical executive with more than 30 years of leadership experience spanning clinical development, regulatory strategy and operational execution appointed to lead company into new phase of clinical development and growth NEW YORK, November 3, 2026 – Anavex Life Sciences Corp. (Nasdaq: AVXL) (“Anavex” or the “Company”), a clinical-stage biopharmaceutical company developing innovative treatments for central nervous […]
Anavex Life Sciences Reports Fiscal 2026 First Quarter Financial Results and Provides Business Update
Company to host a webcast today at 8:30 am Eastern Time NEW YORK – February 9, 2026 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer’s disease, Parkinson’s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central […]